|
|
|
| Webinar: Solving the Inhalation Puzzle: A CDMO's Guide to Dry Powder Development | Dry powders for inhalation (DPIs) represent a versatile delivery platform. However, there are key factors such as required dosage and desired release profiles that dictate the development approach for DPIs. Join Lonza for a webinar that will highlight the key aspects in the product development of inhalation and nasal dry powder products from a CDMO perspective. Click here to learn more. |
|
|
|
|
By Dileep Boinipally, director of drug product formulation, Metsera | This scientific article presents a summary of the formulation development strategy of a JAK1 inhibitor extended-release tablet, with a focus on experimental design, data interpretation, and formulation decision-making. | |
|
|
|
The Role Of A Consulting Firm In The IND Process | White Paper | By Antony Kaprielian and Isaiah Manoogian, Pace Life Sciences | Navigate the complex IND process with expert guidance and discover how early FDA engagement can accelerate your path to clinical trials. |
|
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | It’s a large and universally recognizable CDMO, so this matters. Swiss-based powerhouse Lonza will intensify its focus on biologics, and “advanced synthesis” such as complex modalities including antibody-drug conjugates (ADCs), cell and gene therapies (CGT), and mRNA-based therapeutics. Will other CDMOs follow suit? What does this say about the future of development outsourcing and our industry? | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
Key Considerations For Dry Powder Inhalation | Article | By Carolyn Berg and Carla Vozone, Catalent | A focus on spray-drying expertise in pulmonary and nasal powder development highlights why it is vital to choose the right CDMO. |
|
|
|
Designing Shelf-Stable, Dry Powder Vaccines To Improve Global Access | Article | By John Chen, Access to Advanced Healthcare Institute, and Sana Hosseini and Kim Shepard, Lonza | Spray dry technology is being leveraged to create shelf-stable, dry-powder vaccines to treat and prevent the spread of tuberculosis which could significantly improve our global response to disease. |
|
|
|
|
|
| 20-minute capacity and capabilities quick-looks, 20+ brand new CDMO presenters to evaluate for best-fit this quarter – and a (virtual) commitment of less than 20 percent of your day? We're confident you don’t need 20/20 vision to see the value in this! Join us for Outsourced Pharma's July Partner Week – including sessions in Small Molecule API/HPAPI, Small Molecule Finished Dosage Form, ADC, Analytical Services, and Fill/Finish among others. Registration, on-demand access, and interactive Q&A are free. |
|
|
|
Internal Laboratory | Ropack Pharma Solutions | Discover an analytical laboratory seamlessly integrated with manufacturing and packaging operations, which offers dependable chemical and microbiological testing that adheres to cGMP standards. |
|
|
Process Development And Preclinical Manufacturing — India | Pharma Expanse | The Pharma Expanse network currently spans across 9 manufacturing sites in 5 countries and can support discovery, preclinical, clinical and commercial programs for New Chemical Entities (NCEs). Pharma Expanse has an innovative business model that does not add additional costs to your project. Review our network's process development and preclinical manufacturing capabilities below and contact us to simplify your outsourcing solutions. |
|
|
|
OUTSOURCED PHARMA CAPACITY UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
Connect With Outsourced Pharma: |
|
|
|